Coya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from HC Wainwright

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright's price target would suggest a potential upside of 206.12% from the company's current price.

Several other equities research analysts have also issued reports on COYA. Wall Street Zen lowered Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. D. Boral Capital restated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Tuesday, April 22nd. Finally, Chardan Capital restated a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Coya Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

Coya Therapeutics Stock Performance

Shares of COYA stock opened at $5.88 on Monday. The company has a market capitalization of $98.34 million, a price-to-earnings ratio of -9.05 and a beta of 0.21. Coya Therapeutics has a 52-week low of $4.65 and a 52-week high of $10.24. The company has a 50-day simple moving average of $5.79 and a two-hundred day simple moving average of $6.05.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.44). The business had revenue of $257.88 million during the quarter, compared to analysts' expectations of $2.63 million. On average, sell-side analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Coya Therapeutics

Large investors have recently bought and sold shares of the company. Jane Street Group LLC lifted its position in shares of Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after buying an additional 13,176 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in Coya Therapeutics in the 1st quarter valued at about $65,000. CM Management LLC lifted its holdings in Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after purchasing an additional 40,000 shares during the last quarter. Dauntless Investment Group LLC bought a new position in Coya Therapeutics during the first quarter worth about $1,083,000. Finally, DME Capital Management LP boosted its position in Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock worth $9,434,000 after purchasing an additional 372,414 shares during the period. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.